EpicentRx is a brand focused on developing novel therapies to target cancer and chronic diseases, with a primary goal of improving the efficacy and tolerability of current approved therapies. Led by Tony Reid, a 30-year practicing GI oncologist, EpicentRx is dedicated to changing the perspective of disease treatment by prioritizing patient quality of life during therapy. Their pipeline includes the PRETECT Platform, which features the Phase 3 investigational product, RRx-001, designed to target cancer and chronic inflammatory diseases.

Additionally, EpicentRx offers the AdAPT Platform, which utilizes virus-based immunotherapy technology to create a controlled infection within tumors, stimulating an immune response. They also offer the proprietary eLoop Device for optimized delivery of IV administered treatments. Through their innovative approach and commitment to patient well-being, EpicentRx is revolutionizing the field of disease treatment